Confidentiality: Your privacy is important to us. The information you provide here will be used only by the study sponsor, its affiliated companies and its representatives to fulfill your request to learn more about the COMMANDS Trial, which is studying treatment for myelodysplastic syndromes (MDS), and to assess your eligibility for this trial. If you have any questions about the use of your information, please contact MyData@epharmasolutions.com.
Study participation lasts approximately six years (and may be shorter or longer for some patients). This includes:
• A screening period of approximately 35 days,
• an initial treatment period of 24 weeks (which can be extended if certain criteria are met and if you continue to benefit from treatment), and
• a follow-up period where you will be contacted approximately every 12 weeks to ask how you are doing.
The study drug used in the COMMANDS Trial is a protein that aims to help increase the production of red blood cells in the bone marrow. The study drug will be administered by subcutaneous injection every three weeks during the treatment period.